drugset / Trial / NCT02217852

Treatment of Hypertension in Tibetan Adult Population

NCT02217852

Phase 4 Unknown 800 enrolled West China Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Several surveys had revealed that Tibetan adults had high prevalence of hypertension. However, there was no research studying the antihypertensive effect of the known drugs in Tibetan. The main arms of our study were to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between nitrendipine and Hydrochlorothiazide in mild hypertension in Tibetan, and to determine if the efficacy of lowing blood pressure and protecting target organ damage differs between captopril plus Hydrochlorothiazide and Beijing hypotensive No.0 in moderate and severe Tibetan hypertension.

Timeline

Start
2014-08
Primary completion
2016-01
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Beijing hypotensive No.0 Unknown Oral
Subject Captopril Small molecule 25 mg Oral
Subject Captopril Small molecule 50 mg Oral
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral
Subject Nitrendipine Small molecule 10 mg Oral
Subject Nitrendipine Small molecule 20 mg Oral

Indications